{"nctId":"NCT03548584","briefTitle":"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type","startDateStruct":{"date":"2018-05-16","type":"ACTUAL"},"conditions":["Agitation Associated With Alzheimer's Dementia","Alzheimer Dementia"],"count":345,"armGroups":[{"label":"Brexpiprazole 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]},{"label":"Brexpiprazole 3 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Brexpiprazole","otherNames":["OPC-34712"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with a diagnosis of probable Alzheimer's disease.\n* Participants with a diagnosis of agitation\n* Participants with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.\n* Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.\n* Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.\n* Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.\n* Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.\n* Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.\n\nExclusion Criteria:\n\n* Participants with dementia or other memory impairment not due to Alzheimer's disease.\n* Participants with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.\n* Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.\n* Participants who have been diagnosed with an Axis I disorder.\n* Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.\n* Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.\n* Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 12 in the CMAI Total Score","description":"The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":"1.08"},{"groupId":"OG001","value":"-17.3","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation","description":"CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.06"},{"groupId":"OG001","value":"-0.93","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in CMAI Subscale Scores","description":"The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.09","spread":"0.42"},{"groupId":"OG001","value":"-7.13","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.45","spread":"0.40"},{"groupId":"OG001","value":"-5.04","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.39","spread":"0.31"},{"groupId":"OG001","value":"-3.14","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"0.17"},{"groupId":"OG001","value":"-1.14","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period","description":"The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.76","spread":"0.71"},{"groupId":"OG001","value":"-6.61","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"0.82"},{"groupId":"OG001","value":"-11.0","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"0.91"},{"groupId":"OG001","value":"-13.9","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.4","spread":"0.96"},{"groupId":"OG001","value":"-14.4","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":"0.97"},{"groupId":"OG001","value":"-15.7","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":"1.08"},{"groupId":"OG001","value":"-17.3","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period","description":"CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.03"},{"groupId":"OG001","value":"-0.27","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.05"},{"groupId":"OG001","value":"-0.50","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.05"},{"groupId":"OG001","value":"-0.68","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.06"},{"groupId":"OG001","value":"-0.70","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.06"},{"groupId":"OG001","value":"-0.86","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.06"},{"groupId":"OG001","value":"-0.93","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period","description":"CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"0.75"},{"groupId":"OG001","value":"3.57","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"0.85"},{"groupId":"OG001","value":"3.39","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.92","spread":"0.94"},{"groupId":"OG001","value":"3.19","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"1.00"},{"groupId":"OG001","value":"3.16","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"0.99"},{"groupId":"OG001","value":"2.97","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":"1.09"},{"groupId":"OG001","value":"2.97","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period","description":"The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"37.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"38.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","spread":null},{"groupId":"OG001","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.62","spread":null},{"groupId":"OG001","value":"3.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":null},{"groupId":"OG001","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.89","spread":null},{"groupId":"OG001","value":"5.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"8.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"8.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period","description":"The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]}]},{"type":"SECONDARY","title":"CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period","description":"CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.98","spread":null},{"groupId":"OG001","value":"5.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"40.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":73},"commonTop":["Headache"]}}}